Open AccessOBSERVATIONAL STUDY ON CLINICAL FEATURES, TREATMENT AND OUTCOME OF COVID 19 IN A TERTIARY CARE CENTRE IN INDIA - A RETROSPECTIVE CASE SERIES
Author(s) -
Raja Bhattacharya,
Indranil Ray,
Rishav Mukherjee,
Sampurna Chowdhury,
Manish Kulasreshtha,
Rumi Ghosh
Publication year - 2020
Publication title -
international journal of scientific research
Language(s) - English
DOI - 10.36106/ijsr/7232245
Subject(s) - medicine , case fatality rate , retrospective cohort study , diabetes mellitus , tertiary care , covid-19 , pediatrics , disease , epidemiology , infectious disease (medical specialty) , endocrinology
Till date, no proven therapy exists for treatment of SARS-coV-2 infections which has been de-clared a pandemic by WHO in March, 2020. Objective: This study will attempt to explore the demographic profile and outcome in the pa-tients receiving multidisciplinary, personalised approach including use of Broad Spectrum Antivi-rals - Ivermectin, anti-inflammatory and antioxidants roles of Statins and N-acetyl-cysteine along with Standard of Care (SOC) in hospitalised COVID19 patients in a tertiary care centre. Setting: Inpatient department (designated COVID ward) Participants: COVID-19 patients with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the year 2020 between June 14- 28, 2020. Main outcome measures: The outcome of Interests are : a. Studying the demographic profile of COVID 19 cases b. Study the treatment outcomes in terms of death or discharge in patients receiving Ivermectin+N-acetyl-cysteine+Statin along with Standard of care. Results: 148 patients were included in the study. All of them had confirmed COVID19 infec-tion by the rtPCR method. Average age of the patients was 57.57 years ( Range = 17 - 88), 49% were male, 51% female. 81% of the patients had at least one or more comorbidities. Most com-mon comorbidities included diabetes( 32%), Hypertension (27%),Ischaemic Heart Disease (8%). More comorbidities. The in hospital, Case Fatality Rate was 1.35 %. The remaining 146 were dis-charged from the facility after an average 12 days duration of stay. Conclusions:. Triple therapy with Ivermectin, N-acetyl-cysteine and Atorvastatin along with standard of care is safe and effective in SARS-coV-2 infection.